Pharvaris NV
NASDAQ:PHVS
Pharvaris NV
Research & Development
Pharvaris NV
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pharvaris NV
NASDAQ:PHVS
|
Research & Development
-€98.6m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-77%
|
CAGR 10-Years
N/A
|
|
Pharvaris NV
Glance View
Pharvaris NV is a clinical-stage biopharmaceutical company. The company is headquartered in Leiden, Zuid-Holland and currently employs 34 full-time employees. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).
See Also
What is Pharvaris NV's Research & Development?
Research & Development
-98.6m
EUR
Based on the financial report for Dec 31, 2024, Pharvaris NV's Research & Development amounts to -98.6m EUR.
What is Pharvaris NV's Research & Development growth rate?
Research & Development CAGR 5Y
-77%
Over the last year, the Research & Development growth was -50%. The average annual Research & Development growth rates for Pharvaris NV have been -40% over the past three years , -77% over the past five years .
